In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase

Drug Metabolism and Disposition

Volumn 38, Issue 7, 2010, Pages 1113-1121

  Hutzler, J Matthew ^a,b   Linder, Collette D ^a   Melton, Roger J ^a,c   Vincent, John ^a   Daniels, J Scott ^a  

^a PFIZER INC   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c Seventh Wave Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 (4 (2 METHYL 1H IMIDAZOL 1 YL)PHENYLTHIO)PHENYL) TETRAHYDRO 2H PYRAN 4 CARBOXAMIDE; CJ 13 610; COMPLEMENTARY DNA; CYTOCHROME P450; KETOCONAZOLE; LIPOXYGENASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG; CJ 13610; CYTOCHROME P450 INHIBITOR; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; SULFIDE;

ALLOMETRY; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; MICHAELIS MENTEN KINETICS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; RAT; SULFOXIDATION; ANIMAL; BIOLOGICAL MODEL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; KINETICS; PHASE 1 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SPRAGUE DAWLEY RAT;

CANIS FAMILIARIS; RATTUS;

ANIMALS; CYTOCHROME P-450 ENZYME INHIBITORS; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; IN VITRO TECHNIQUES; KINETICS; LIPOXYGENASE INHIBITORS; MALE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; SULFIDES;

EID: 77953751021     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032706     Document Type: Article

References (28)

1. Banker MJ, Clark TH, and Williams JA (2003) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967-974.
2. Becker A (2000) Clinical evidence with montelukast in the management of chronic childhood asthma. Drugs 59 (Suppl 1):29-34.
3. Cashman JR (2000) Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab 1:181-191.
4. Chiou WL and Barve A (1998) Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15:1792-1795.
5. Cortes-Burgos LA, Zweifel BS, Settle SL, Pufahl RA, Anderson GD, Hardy MM, Weir DE, Hu G, Happa FA, Stewart Z, Muthian S, Graneto MJ, and Masferrer JL (2009) CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain. Eur J Pharmacol 617:59-67.
6. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, and Smith DA (2009) Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357-368.
7. Fischer L, Steinhilber D, and Werz O (2004) Molecular pharmacological profile of the nonredoxtype 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol 142:861-868.
8. Gilissen RA, Ferrari L, Barnaby RJ, and Kajbaf M (2000) Human hepatic metabolism of a novel 2-carboxyindole glycine antagonist for stroke: in vitro-in vivo correlations. Xenobiotica 30:843-856.
9. Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, and Awni WM (1995) Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 29 (Suppl 2):77-83.
10. Horrillo R, Planagumà A, González-Périz A, Ferré N, Titos E, Miquel R, López-Parra M, Masferrer JL, Arroyo V, and Clària J (2007) Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. J Pharmacol Exp Ther 323:778-786.
11. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ,Webster R, and Beaumont K (2009) Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533.
12. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
13. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171. (Pubitemid 27191615)
14. Kuperman AV, Kalgutkar AS, Marfat A, Chambers RJ, and Liston TE (2001) Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue. Drug Metab Dispos 29:1403-1409. (Pubitemid 33000686)
15. Liu MC, Dubé LM, and Lancaster J (1996) Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol 98:859-871.
16. Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, and Rodrigues AD (2003) Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 31:1352-1360.
17. Obach RS (1997) Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359-1369.
18. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
19. Obach RS (2000) Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos 28:1069-1076.
20. Obach RS (2001) The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Dev 4:36-44.
21. Obach RS, Margolis JM, and Logman MJ (2007) In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino] piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet 22:336-349.
22. Racha JK, Zhao ZS, Olejnik N, Warner N, Chan R, Moore D, and Satoh H (2003) Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab Pharmacokinet 18:128-138.
23. Reiss TF, Altman LC, Chervinsky P, Bewtra A, Stricker WE, Noonan GP, Kundu S, and Zhang J (1996) Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 98:528-534.
24. Samuelsson B (1983) Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220:568-575. (Pubitemid 13130140)
25. Störmer E, Roots I, and Brockmöller J (2000) Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol 50:553-561.
26. Wenzel SE and Kamada AK (1996) Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann Pharmacother 30:858-864. (Pubitemid 26243935)
27. Werz O and Steinhilber D (2006) Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 112:701-718.
28. Zweifel BS, Hardy MM, Anderson GD, Dufield DR, Pufahl RA, and Masferrer JL (2008) A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors. Eur J Pharmacol 584:166-174.